Brokerages Set Rallybio Corporation (NASDAQ:RLYB) Price Target at $5.00

Shares of Rallybio Corporation (NASDAQ:RLYB) have been assigned a consensus rating of “Reduce” from the five analysts that are presently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation and four have assigned a hold recommendation to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $5.00.

Several research analysts have recently issued reports on RLYB shares. Wall Street Zen cut Rallybio from a “hold” rating to a “sell” rating in a research note on Sunday, October 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Rallybio in a research report on Monday, December 15th.

Rallybio Price Performance

Shares of RLYB opened at $0.76 on Wednesday. The company’s fifty day moving average price is $0.66 and its 200-day moving average price is $0.55. Rallybio has a 1-year low of $0.22 and a 1-year high of $1.08. The firm has a market capitalization of $31.90 million, a PE ratio of -2.36 and a beta of -1.05.

Rallybio (NASDAQ:RLYB) last issued its earnings results on Thursday, November 6th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.11. The company had revenue of $0.21 million during the quarter, compared to analyst estimates of $0.07 million. Rallybio had a negative return on equity of 65.23% and a negative net margin of 2,102.37%. As a group, research analysts anticipate that Rallybio will post -1.34 EPS for the current fiscal year.

Institutional Trading of Rallybio

An institutional investor recently raised its position in Rallybio stock. Citadel Advisors LLC boosted its holdings in shares of Rallybio Corporation (NASDAQ:RLYB) by 576.1% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 438,705 shares of the company’s stock after purchasing an additional 373,821 shares during the period. Citadel Advisors LLC owned about 1.04% of Rallybio worth $219,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 90.34% of the stock is currently owned by institutional investors.

Rallybio Company Profile

Rallybio Therapeutics, Inc (NASDAQ: RLYB) is a clinical‐stage biotechnology company focused on developing and commercializing therapies for people living with rare genetic diseases. The company’s scientific approach leverages diverse modalities—including monoclonal antibodies, small molecules and enzyme replacement—to address high‐unmet‐need conditions in areas such as immunodeficiency, metabolic disorders and dermatologic diseases. Rallybio’s pipeline is designed to advance through registrational clinical trials with the goal of delivering first‐in‐class or best‐in‐class therapies to patients who currently have limited or no approved treatment options.

Among Rallybio’s lead programs is RBX‐100, an investigational therapy for congenital athymia, a rare pediatric immunodeficiency.